TY  - JOUR
AU  - Hilario Barrio, Amaya
AU  - Sepulveda, J.M.
AU  - Hernández Laín, Aurelio
AU  - Salvador Álvarez, Elena
AU  - Koren, L.
AU  - Manneh, R.
AU  - Ruano, Y.
AU  - Pérez Núñez, Ángel
AU  - Lagares Gómez-Abascal, Alfonso
AU  - Ramos González, Ana
PY  - 2017
DO  - 10.1007/s12094-016-1502-4
SN  - 1699-3055
UR  - https://hdl.handle.net/20.500.14352/116736
T2  - Clinical and Translational Oncology
AB  - Background and purpose: In glioblastoma, tumor progression appears to be triggered by expression of VEGF, a regulator of blood vessel permeability. Bevacizumab is a monoclonal antibody that inhibits angiogenesis by clearing circulating VEGF, resulting...
LA  - eng
M2  - 51
PB  - Springer Nature
KW  - glioma
KW  - RM
KW  - Bevacizumab
TI  - Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab
TY  - journal article
VL  - 19
ER  -